Levamisole in postoperative adjuvant immunochemotherapy for gastric cancer |
| |
| Authors: | Minoru Niimoto Takao Hattori Ichiji Ito Ryuichiro Tamada Kiyoshi Inokuchi Kunzo Orita Hisashi Furue Nobuya Ogawa Tomohiro Toda Motonosuke Furusawa Shigemasa Koga Isamu Hashimoto Tatsuhei Kondo Shigeru Fujimoto Yuzuru Sugiyama Osahiko Abe Masaaki Oya |
| |
| Institution: | (1) Department of Surgery, Research Institute for Nuclear Medicine and Biology, Hiroshima University, 1-2-3, Kasumi, Minami-ku, 734 Hiroshima, Japan;(2) Dept. of Surgery, Tokyo Metropolitan Komagome Hospital, Japan;(3) Dept. of Surgery, Kyushu University, Japan;(4) Dept. of Surgery, Okayama University, Japan;(5) Dept. of Internal Medicine, Teikyo University, Japan;(6) Dept. of Pharmacology, Ehime University, Japan;(7) Dept. of Surgery, Hofu Gastrointestinal Hospital, Japan;(8) Dept. of Surgery, National Kyushu Cancer Center Hospital, Japan;(9) Dept. of Surgery, Tottori University, Japan;(10) Dept. of Surgery, Kyoto Prefectural University of Medicine, Japan;(11) Dept. of Surgery, Nagoya University, Japan;(12) Dept. of Surgery, Chiba University, Japan;(13) Dept. of Surgery, Hirosaki University, Japan;(14) Dept. of Surgery, Keio University, Japan;(15) Dept. of Surgery, Kita-Osaka Research Institute for Gastrointestinal Disease Center, Japan |
| |
| Abstract: | Summary The usefulness of LMS in postoperative immunochemotherapy of gastric cancer was investigated. In compliance with the protocol, MMC was given at a dose of 20 mg on the day of gastrectomy, and an additional 10 mg on the next day IV. The patients receiving 600 mg Tegafur daily were then divided into two groups according to whether LMS was also given or not. LMS was administered for 3 days before the operation in a daily dose of 150 mg and for 1 year or more after operation according to a schedule of 3 days' administration followed by an 11-day interval. The 2-year follow-up demonstrated that in stage III patients, the LMS (+) regimen was superior to the LMS (–) regimen, since the former prolonged the relapse-free interval significantly. The survival rate for stage III disease was also significantly higher in the LMS (+) than in the LMS (–) group. There was no significant difference in the incidence of subjective or objective side-effects between two groups. The incidence of agranulocytosis was comparable in the two groups.Gastrointestinal Cancer Research Group, Japan Levamisole Research AssociationChairmen of the Gastrointestinal Cancer Research Group, Japan LMS Research AssociationController of the Gastrointestinal Cancer Research Group, Japan LMS Research AssociationMembers of the Data Collection and Analysis SubcommitteeThis study was carried out by the Gastrointestinal Cancer Research Group, Japan LMS Research Association (directed by Prof. Kiyoshi Inokuchi, Dept. of Surgery, Kyushu University and Prof. Eiro Tsubura, Dept. of Internal Medicine, Tokushima University). The results were presented in part at the 19th General Meeting of the Japanese Society for Gastroenterological Surgery in February, 1982 |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
